Key Performance
More- Earnings Score: 38
- Momentum Score: 62
- True Yield: N/A
- Financial Health Score: 0
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
The cell and gene therapy CDMO market is projected to grow from USD 8.3 billion in 2025 to USD 57.1 billion by 2034, driven by increasing clinical development of advanced therapies, rising outsourcing trends among biopharma companies, and technological advancements in manufacturing. North America leads the market with 40% share, while Asia-Pacific emerges as a significant growth hub. Key players are expanding manufacturing capabilities through strategic partnerships.
06/18/2026, 1:00 PM • GlobeNewswire
The cell banking outsourcing market is projected to grow from USD 16.78 billion in 2025 to USD 42.31 billion by 2031, with a CAGR of 16.71%. Growth is driven by increasing demand for biologics, cell and gene therapies, and regenerative medicine. North America leads the market while Asia-Pacific emerges as a high-growth region. Biopharmaceutical companies are increasingly outsourcing cell banking operations to improve efficiency and reduce costs.
05/25/2026, 4:15 AM • GlobeNewswire
The plasmid DNA manufacturing market is projected to grow from USD 2.4 billion in 2025 to USD 10.8 billion by 2034, driven by rising demand for gene therapies, DNA vaccines, and CAR-T treatments. North America leads the market with 44.12% share, while Asia-Pacific emerges as a significant growth engine. Major companies are expanding GMP-compliant manufacturing capabilities to meet increasing demand from biopharmaceutical companies and CDMOs.
05/04/2026, 1:00 PM • GlobeNewswire
The AAV vector manufacturing market is projected to grow from USD 874 million in 2025 to USD 5.2 billion by 2034, driven by expanding gene therapy research, increasing regulatory approvals, and rising investments in biomanufacturing infrastructure. North America leads the market with 43% share, while Asia-Pacific emerges as a key growth engine. Key drivers include growing prevalence of genetic disorders, technological advancements in manufacturing, and expansion of outsourcing to CDMOs.
04/28/2026, 1:00 PM • GlobeNewswire
The drug development services market is projected to grow from $28.09 billion in 2025 to $50.26 billion by 2030 at a CAGR of 12.4%, driven by increased R&D investments, AI adoption, personalized medicine, and emerging market expansion. Key growth areas include preclinical research, regulatory optimization, and cloud-based data management, with precision medicine and genomics advancements playing pivotal roles.
04/14/2026, 10:59 AM • GlobeNewswire
ResearchAndMarkets.com is offering a two-day online training course (May 13-14, 2026) on implementing VICH Good Clinical Practice principles in veterinary clinical trials. The course aims to enhance trial efficiency, ensure regulatory compliance, and improve data quality for EU and USA acceptance. It covers protocol design, data management, monitoring, and quality assurance with expert instructors including Donna Taylor and Jenny Webster.
04/14/2026, 4:58 AM • GlobeNewswire
The global Pharmaceutical Microbiology QC Testing Market is projected to grow from USD 5.08 billion in 2025 to USD 17.65 billion by 2035, at a CAGR of 13.27%. Growth is driven by increased regulatory oversight, laboratory automation, antimicrobial resistance concerns, and adoption of advanced technologies like AI-enabled molecular platforms and MALDI-TOF mass spectrometry. North America leads with 39.12% market share, while Asia Pacific is expected to grow fastest at 14.33% CAGR.
03/10/2026, 2:00 PM • GlobeNewswire
Charles River Labs Breaks The Mold, Announces Bold Divestiture Plans
Charles River Laboratories announced significant divestiture plans, selling its CDMO and Cell Solutions businesses to GI Partners, and certain European Discovery Services assets to IQVIA Holdings. The divestitures will reduce 2026 revenue by over $200 million but are expected to improve adjusted operating margins by at least 100 basis points and add approximately 10 cents to adjusted EPS. The company raised its fiscal 2026 adjusted earnings guidance to $10.80-$11.30.
02/25/2026, 9:06 AM • Benzinga
The global Adeno Associated Virus (AAV) vector manufacturing market is projected to grow from USD 2.84 billion in 2025 to USD 9.87 billion by 2035, at a CAGR of 13.4%. Growth is driven by increased clinical trials, regulatory approvals of AAV-based gene therapies, technological innovations in manufacturing processes, and rising demand from pharmaceutical companies and CDMOs. North America leads the market while Asia Pacific shows the fastest growth rate.
02/03/2026, 1:00 PM • GlobeNewswire
The global lead optimization services in drug discovery market is projected to grow from USD 4.26 billion in 2024 to USD 10.26 billion by 2034, driven by rising R&D activities, technological advancements, and increasing outsourcing trends in pharmaceutical research.
11/28/2025, 10:00 AM • GlobeNewswire
Innovative Drug CRO Market to Soar USD 96.06 Billion by 2035, Expanding at 5.44% CAGR
The global innovative drug CRO market is projected to grow from USD 59.63 billion in 2026 to USD 96.06 billion by 2035, with a 5.44% CAGR, driven by increasing R&D costs, clinical trial complexities, and technological advancements.
11/28/2025, 9:00 AM • GlobeNewswire
Charles River Beat Expectations But Why Is The Stock Falling?
Charles River Laboratories reported Q3 2025 earnings beating expectations, with revenue of $1.01 billion, but lowered full-year guidance and announced strategic asset sales, causing stock to decline.
11/05/2025, 1:38 PM • Benzinga
The global cell-based assays market is projected to grow from USD 17.11 billion in 2023 to USD 35.34 billion by 2032, driven by increasing demand in drug discovery, toxicity testing, and advanced biotechnology research.
10/30/2025, 4:59 AM • GlobeNewswire
Cell & Gene Therapy Quality Control Market Poised USD 22.81 Billion at 25.74% CAGR by 2034
The global cell and gene therapy quality control market is projected to grow from $2.87 billion in 2025 to $22.81 billion by 2034, with a 25.74% CAGR. North America currently leads the market, while Asia Pacific is expected to witness the fastest growth, driven by technological advancements and increasing demand for personalized therapies.
10/29/2025, 9:00 AM • GlobeNewswire
Biologics Safety Testing Market to Rise at 13.64% CAGR, Soars USD 14.45 Bn by 2034
The global biologics safety testing market is projected to grow from $4.58 billion in 2025 to $14.45 billion by 2034, with a 13.64% CAGR. North America dominates the market, driven by biopharmaceutical R&D and technological advancements, while Asia-Pacific shows rapid growth potential.
10/16/2025, 11:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.